Enhanced Intracellular Delivery of BCG Cell Wall Skeleton into Bladder Cancer Cells Using Liposomes Functionalized with Folic Acid and Pep-1 Peptide.

bacillus Calmette–Guérin bladder cancer cell wall skeleton cell-penetrating peptide folate ligand liposome targeted delivery

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
04 Dec 2019
Historique:
received: 14 11 2019
revised: 28 11 2019
accepted: 02 12 2019
entrez: 11 12 2019
pubmed: 11 12 2019
medline: 11 12 2019
Statut: epublish

Résumé

Although bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) might function as a potential substitute for live BCG, its use in the treatment of bladder cancer remains limited owing to issues such as insolubility and micrometer-size following exposure to an aqueous environment. Thus, to develop a novel nanoparticulate system for efficient BCG-CWS delivery, liposomal encapsulation was carried out using a modified emulsification-solvent evaporation method (targets: Size, <200 nm; encapsulation efficiency, ~60%). Further, the liposomal surface was functionalized with specific ligands, folic acid (FA), and Pep-1 peptide (Pep1), as targeting and cell-penetrating moieties, respectively. Functionalized liposomes greatly increased the intracellular uptake of BCG-CWS in the bladder cancer cell lines, 5637 and MBT2. The immunoactivity was verified through elevated cytokine production and a THP-1 migration assay. In vivo antitumor efficacy revealed that the BCG-CWS-loaded liposomes effectively inhibited tumor growth in mice bearing MBT2 tumors. Dual ligand-functionalized liposome was also superior to single ligand-functionalized liposomes. Immunohistochemistry supported the enhanced antitumor effect of BCG-CWS, with IL-6 production and CD4 infiltration. Thus, we conclude that FA- and Pep1-modified liposomes encapsulating BCG-CWS might be a good candidate for bladder cancer treatment with high target selectivity.

Identifiants

pubmed: 31817179
pii: pharmaceutics11120652
doi: 10.3390/pharmaceutics11120652
pmc: PMC6970232
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministry of Health and Welfare, Republic of Korea through the Korea Health Industry Development Institute (KHIDI)
ID : HI17C0710
Organisme : Korea government (MSIT) through the National Research Foundation of Korea (NRF)
ID : 2019R1A2C2002510

Déclaration de conflit d'intérêts

The authors declare no conflict of interests.

Références

Mol Pharm. 2015 Dec 7;12(12):4200-13
pubmed: 26544061
Int J Pharm. 2017 May 15;523(1):229-237
pubmed: 28341149
Pharm Res. 2010 Jan;27(1):161-74
pubmed: 19862607
Nat Rev Urol. 2014 Mar;11(3):153-62
pubmed: 24492433
J Control Release. 2015 Feb 28;200:138-57
pubmed: 25545217
Int J Nanomedicine. 2013;8:1155-65
pubmed: 23515421
J Microbiol Methods. 2009 May;77(2):139-44
pubmed: 19318051
Cancer Res. 1992 Jun 15;52(12):3396-401
pubmed: 1596899
J Urol. 1995 Aug;154(2 Pt 1):572-5
pubmed: 7609139
Br J Cancer. 1995 Apr;71(4):801-7
pubmed: 7710947
Int J Pharm. 2008 May 22;356(1-2):29-36
pubmed: 18258394
J Natl Cancer Inst. 1974 Jan;52(1):95-101
pubmed: 4590014
Br J Cancer. 2004 Aug 16;91(4):607-12
pubmed: 15266312
J Control Release. 2014 Feb 28;176:44-53
pubmed: 24389133
Surg Today. 2009;39(3):194-200
pubmed: 19280277
Mol Pharm. 2018 Dec 3;15(12):5762-5771
pubmed: 30380885
J Drug Target. 2011 Aug;19(7):497-505
pubmed: 20738150
Int Immunopharmacol. 2001 Jul;1(7):1249-59
pubmed: 11460306
J Control Release. 2014 Jul 10;185:71-87
pubmed: 24768790
J Urol. 2004 Oct;172(4 Pt 1):1490-5
pubmed: 15371877
Biochem Biophys Res Commun. 2019 Jan 29;509(1):167-174
pubmed: 30579607
Immunotherapy. 2010 Jul;2(4):551-60
pubmed: 20636008
CA Cancer J Clin. 2010 Jul-Aug;60(4):244-72
pubmed: 20566675
J Control Release. 2014 Dec 28;196:161-7
pubmed: 25315488
Drug Discov Today. 2001 Jan 1;6(1):44-51
pubmed: 11165172
J Control Release. 2006 Sep 12;114(3):277-87
pubmed: 16904220
J Control Release. 2010 Feb 15;141(3):320-7
pubmed: 19874859
Lancet Oncol. 2011 Sep;12(9):871-9
pubmed: 21831711
J Urol. 1993 Sep;150(3):1018-23
pubmed: 8102183
Eur J Pharm Biopharm. 2018 Jul;128:156-169
pubmed: 29689288
Int J Nanomedicine. 2019 Aug 05;14:6249-6268
pubmed: 31496684
Cytotherapy. 2017 Oct;19(10):1233-1245
pubmed: 28818454
PLoS One. 2019 Jan 4;14(1):e0209196
pubmed: 30608942
Cancer Res. 1979 Aug;39(8):3262-7
pubmed: 222448
J Pharm Investig. 2018 Jan;48(1):89-111
pubmed: 29963321
Pharm Res. 2010 Aug;27(8):1687-702
pubmed: 20552255

Auteurs

Ho Yub Yoon (HY)

Drug Delivery Research Lab, College of Pharmacy, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Korea.

Hee Mang Yang (HM)

Drug Delivery Research Lab, College of Pharmacy, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Korea.

Chang Hyun Kim (CH)

Drug Delivery Research Lab, College of Pharmacy, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Korea.

Yoon Tae Goo (YT)

Drug Delivery Research Lab, College of Pharmacy, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Korea.

Gwang Yong Hwang (GY)

Department of Urology, College of Medicine, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Korea.

In Ho Chang (IH)

Department of Urology, College of Medicine, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Korea.

Young Mi Whang (YM)

Department of Internal Medicine, Seoul National University Hospital 101, Daehak-ro, Jongno-gu, Seoul 03080, Korea.

Young Wook Choi (YW)

Drug Delivery Research Lab, College of Pharmacy, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Korea.

Classifications MeSH